Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Shares Issued (2016 - 2024)

Fate Therapeutics' Shares Issued history spans 12 years, with the latest figure at -$19.7 million for Q4 2024.

  • For Q4 2024, Shares Issued fell 7334.34% year-over-year to -$19.7 million; the TTM value through Sep 2025 reached -$19.7 million, down 199.85%, while the annual FY2024 figure was $295000.0, N/A changed from the prior year.
  • Shares Issued reached -$19.7 million in Q4 2024 per FATE's latest filing, up from -$54.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $54.5 million in Q2 2024 to a low of -$54.5 million in Q3 2024.
  • Average Shares Issued over 5 years is $1.1 million, with a median of $2.2 million recorded in 2022.
  • The largest YoY upside for Shares Issued was 20479.25% in 2024 against a maximum downside of 7334.34% in 2024.
  • A 5-year view of Shares Issued shows it stood at $4.9 million in 2020, then crashed by 523.34% to -$20.7 million in 2021, then surged by 107.34% to $1.5 million in 2022, then plummeted by 117.47% to -$265000.0 in 2023, then plummeted by 7334.34% to -$19.7 million in 2024.
  • Per Business Quant, the three most recent readings for FATE's Shares Issued are -$19.7 million (Q4 2024), -$54.5 million (Q3 2024), and $54.5 million (Q2 2024).